NCT00148772View on ClinicalTrials.gov

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Prostate Cancer
Interventions
DRUG

Erlotinib (Tarceva)

Trial Locations (2)

60201

Evanston Northwestern Healthcare, Evanston

60611

Northwestern University, Chicago

Sponsors

Lead Sponsor

Endeavor Health

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Northwestern University

OTHER

lead

Endeavor Health

OTHER

NCT00148772 - Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy | Biotech Hunter | Biotech Hunter